April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.12 USD | +0.74% | -11.26% | +61.75% |
09/05 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
07/05 | ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.75% | 5.62B | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.23% | 22.25B | |
-13.14% | 22.09B | |
-7.68% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- U.S. FDA approves ImmunityBio's bladder cancer therapy